SCHEMBL4242203

SCHEMBL4242203

CCC(CC)NC(=O)Nc1cc(OC)c(Oc2ccc(NC(=O)c3ccc(OC4CCN(Cc5ccccc5)CC4)c(C)c3)cc2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 3/20 0.42
POLB P06746 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
MAPT P10636 3/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HSD17B10 Q99714 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MCHR1 Q99705 1/20 0.41
CCR5 P51681 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
KMT2A Q03164 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236713 0.90 MCHR1 (0.41) POLBMAPTLMNAMCHR1PDE4A
SCHEMBL4233744 0.90 MAPT (0.39) POLBMAPTLMNASMN1; SMN2MCHR1
SCHEMBL4236270 0.89 MCHR1 (0.39) POLBMAPTLMNAMCHR1RAB9A
SCHEMBL4232148 0.89 MCHR1 (0.40) POLBMAPTLMNAMCHR1PDE4A
SCHEMBL4683749 0.87 LMNA (0.39) POLBMAPTLMNAMCHR1KMT2A
SCHEMBL4236259 0.87 BCL9 (0.45) MAPTLMNAPDE4APDE4BPDE4C
SCHEMBL4237351 0.86 LMNA (0.39) POLBMAPTLMNAMCHR1KMT2A
SCHEMBL4236667 0.84 TAS1R3 (0.40) POLBMAPTLMNASMN1; SMN2HSD17B10
SCHEMBL4236614 0.84 MAPT (0.52) ACKR3MAPTLMNASMN1; SMN2HSD17B10
SCHEMBL4234434 0.84 LMNA (0.40) POLBMAPTLMNAMCHR1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R ACKR3 319/4885POLB 4249/4885SIGMAR1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.